Dermatology

A dermatologist discusses how to care for patients with psoriasis during the COVID-19 pandemic.

Enjoy our archived discussion between 4 experts on how their specialty is most affected by the pandemic.

A systematic review and meta-analysis show the systemic therapies, as well as a couple investigational biologics, may be superior.

The treatment was initially approved for adults >18 years old.

The free webinar, "Derm Clinical Updates: Keeping Up with COVID-19," will feature a four-expert panel fielding topics on therapies, immunocompromised patients, telemedicine, surgery, and more.

The IL-17A-targeting biologic has now been indicated for pediatric plaque psoriasis—marking its fourth indication for patients with chronic diseases.

Clinical investigator and allergist Jonathan Corren, MD, shares insight on the TSLP inhibitor.

New phase 3 IMMhance findings show durable, sustained effect of the IL-23 inhibitor on a 12-week dose regimen.

New pivotal phase 3 findings support an upcoming sBLA for the IL4 and IL13-targeting agent.

Lisa Stein Gold, MD, of Henry Ford Hospital discusses promising phase 2 data for a new PDE4 inhibitor.

Low fecal intestinal secretory immunoglobin A is commonly found in infants of mothers in the antepartum and persistent depression trajectories.

New data evidences yet another IL-13 targeting biologic for atopic dermatitis.

The Ready, Set, Food! co-founder discusses how research and federal advisory shapes parental understanding of immunotherapy and food allergy prevention.